



Correction to: Effect of Renal Impairment on Pharmacokinetics and Safety of Ensitrelvir, a SARS-CoV-2 3CL Protease Inhibitor

Takayuki Katsube · Safwan Kezbor · Ryosuke Shimizu · Ryuji Kubota

Published online: 13 August 2024
© The Author(s) 2024

Correction to:

Infect Dis Ther (2024) 13:597–607
<https://doi.org/10.1007/s40121-024-00946-x>

In the original version of this article, legend of Fig. 1 was incorrect. The correct legend of Fig. 1 is given below. The original article has been corrected

Fig. 1 Mean (standard deviation) pharmacokinetic profiles of normal renal impairment participants and participants with renal impairment following single-dose administration of ensitrelvir 375 mg. Plasma concentrations of participants

The original article can be found online at <https://doi.org/10.1007/s40121-024-00946-x>.

T. Katsube (✉) · R. Shimizu · R. Kubota
Clinical Pharmacology and Pharmacokinetics,
Shionogi & Co., Ltd., 3-13, Imabashi 3-Chome,
Chuo-Ku, Osaka 541-0042, Japan
e-mail: takayuki.katsube@shionogi.co.jp

R. Shimizu
e-mail: ryosuke.shimizu@shionogi.co.jp

R. Kubota
e-mail: ryuji.kubota@shionogi.co.jp

S. Kezbor
Shionogi Inc., 400 Campus Drive, 4th Fl.,
Florham Park, NJ 07932, USA
e-mail: Safwan.Kezbor@shionogi.com

with normal renal impairment, open triangles; with mild renal impairment, filled circles; with moderate renal impairment, open circles; with severe renal impairment, filled triangles. The figures are in linear (upper) and semilogarithmic (lower) scales.

Open Access. This article is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License, which permits any non-commercial use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <http://creativecommons.org/licenses/by-nc/4.0/>.

Publisher's Note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.